Innoviva Inc INVA

NAS: INVA | ISIN: US45781M1018 17/05/2024

15,98 USD (0,00%)

(0,00%) 17/05/2024

Grafiek Innoviva Inc

Grafiek Innoviva Inc

1 dag1d 0,00%
1 week1w -1,30%
1 maand1m 7,03%
3 maanden3m 1,14%
6 maanden6m 17,33%
1 jaar1j 17,16%
5 jaar5j 12,46%

Innoviva Inc in het nieuws

Toon enkel gratis nieuws

4 maart 2024 · Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with Innoviva · Persbericht

11 juli 2023 · Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics · Persbericht

10 januari 2023 · Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC · Persbericht

31 maart 2022 · Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $45 Million Private Placement with Innoviva · Persbericht

9 februari 2022 · Armata Pharmaceuticals Announces $45 Million Investment to Support Advancement of the Company's Bacteriophage Development · Persbericht

17 maart 2021 · Armata Pharmaceuticals Announces Closing of Second and Final Tranche of $20 Million Private Placement with Innoviva · Persbericht

27 januari 2021 · Armata Pharmaceuticals Announces $20 Million Investment to Support Advancement of the Company's Bacteriophage Development Programs · Persbericht

Profiel Innoviva Inc

Fabricage van farmaceutische preparaten

Farmaceutische producten: Andere

Gezondheidstechnologie

Website: www.inva.com

Hoofdzetel: Brisbane, California Verenigde Staten

CEO: Geoffrey Hulme

Werknemers: 13

Aandelen Innoviva Inc

Beurswaarde: 997,87 miljoen USD

Effecten: 62,44 miljoen

Winst per aandeel (12 maand): PLUS

Koers-winstverhouding: PLUS

Beta: 0,51

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe